Quantum BioPharma Ltd.

Quantum BioPharma Ltd. announced a significant advancement in its clinical pipeline by entering into a binding Letter of Intent with Allucent, a global contract research organization specializing in central nervous system trials. This partnership is centered on the planned Phase 2 clinical trial for Lucid-MS, the company's lead compound targeting multiple sclerosis (MS). The collaboration leverages Allucent's deep expertise in neuroscience and MS trials to support comprehensive clinical services, including regulatory submissions, site management, patient recruitment, and data integrity oversight. Management highlighted that this partnership is expected to support efficient execution of the trial, which is anticipated to begin in the second quarter of 2026, contingent upon regulatory approvals and final operational arrangements.

Lucid-MS represents a potentially differentiated therapeutic approach in the MS market. Unlike existing treatments that primarily modulate the immune system, Lucid-MS is designed to inhibit demyelination—a key driver of disease progression—thereby offering neuroprotection. Preclinical models have shown the compound's ability to prevent and reverse myelin degradation. The Phase 2 trial aims to evaluate the efficacy, safety, and tolerability of this novel mechanism. With MS affecting approximately 2.8 million people globally and the therapeutic market projected to exceed $38 billion by 2030, the successful advancement of Lucid-MS could position Quantum BioPharma to address a significant unmet medical need and capture market share in the neuroprotective segment. The transition to a definitive services agreement in the coming weeks will solidify this strategic partnership.